Head to head · SEC data as of September 11, 2026
AbbVie
60
Quality score · out of 100
Johnson & Johnson
81
Quality score · out of 100
Johnson & Johnson comes in ahead: a quality score of 81 versus 60 for AbbVie. Johnson & Johnson wins on net margin (21.5% vs 9.8%) and less debt (0.84× vs 3.31×). AbbVie answers with cash generation (FCF) (28.3% vs 22.7%) and revenue growth (6.4% vs 3.2%).
| Metric | AbbVie | Johnson & Johnson |
|---|---|---|
| Quality score (0-100) | 60 | 81 |
| Net margin | 9.8% | 21.5% |
| Gross margin | — | 67.9% |
| ROE | — | 24.8% |
| Net debt/EBITDA | 3.31× | 0.84× |
| FCF margin | 28.3% | 22.7% |
| Revenue growth (annualized) | 6.4% | 3.2% |
| Earnings growth (annualized) | 4.9% | 8.5% |
TTM metrics with official SEC data, refreshed daily. Bold green marks the winner of each metric. A dash means the metric doesn't apply or isn't reliable.
AbbVie. AbbVie is a large U.S. pharmaceutical company. For years it relied on a single blockbuster drug (Humira); today its challenge is to grow with its new generation of medicines, especially in immunology and aesthetics.
Johnson & Johnson. Johnson & Johnson is one of the world's largest health companies. After spinning off its consumer division, it focuses on two businesses: medicines (pharmaceuticals) and medical devices (medtech).
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
What this comparison doesn't tell you
The score measures business quality, not whether the stock is cheap or expensive: the better company can be the worse investment if you overpay. For the valuation verdict, enter each one's current price in the analyzer:
Who has the stronger fundamentals today, AbbVie or Johnson & Johnson?
By the StockSemáforo model (profitability, growth and financial strength, built on official SEC data), Johnson & Johnson scores higher: 81 versus 60 out of 100. The score is recomputed nightly with the latest filings.
Does that make Johnson & Johnson the better investment?
No. The score measures business quality, not valuation: an excellent company can trade at an excessive price and be a poor investment at that price. To find out whether it's cheap or expensive, enter its current quote in the StockSemáforo analyzer.
Other comparisons
Pfizer vs Merck · Johnson & Johnson vs Pfizer · Eli Lilly vs AbbVie · Amgen vs Gilead · UnitedHealth vs CVS Health · See all comparisons →
Who's behind the methodology and model · how the score is computed
Data: official SEC filings (EDGAR) · Recomputed on September 11, 2026
Spotted a figure that looks wrong? Report it and we'll review it.